Report Overview

United States Gonorrhea Therapeutics Market Size – Industry Trends & Forecast Report 2031

The United States gonorrhea therapeutics market is estimated to have reached USD 456.8 million in 2020 and is further projected to reach USD 892.3 million by 2027, growing at a CAGR of 6.2% during 2021-2031 (forecast period). The gonorrhea therapeutics market is anticipated to grow in the forecast period owing to driving factors such as the Increasing prevalence of gonorrhea, coupled with the rising public awareness about STDs (Sexually-Transmitted Diseases). Moreover, advances in relevant diagnostic methods, rising investments by prominent players for the growing demand are also offering opportunities in the market growth during the forecast period.

Source: BlueWeave Consulting

United States Gonorrhea Therapeutics Market Overview:

Gonorrhea is a sexually transmitted disease (STD). It is caused by the bacterium Neisseria gonorrhoeae. It tends to infect warm, moist areas of the body like the urethra, eyes, throat, vagina, anus, and female reproductive tract. Gonorrhea transfers from person to person through unprotected sex. Newborns can be infected during delivery if their mothers are infected. In infants, a disease most commonly affects the eyes. Symptoms usually happen within two to 14 days after exposure. However, some people affected by gonorrhea never develop prominent symptoms. People are more likely to spread the infection to other partners when they don't have notable symptoms.

United States Gonorrhea Therapeutics Market Forecast and Trends

Growth Drivers 

Rising Prevalence of Gonorrhea 

The United States gonorrhea drug market is growing significantly due to rising gonorrhea prevalence. The growth in the proportion of unprotected sex has led to an escalation. According to the CDC estimates, in 2018, a total of 583,405 cases of gonorrhea were reported in the United States, yielding a rate of 179.1 cases per 100,000 population. During 2017– Nevertheless, the rate of reported gonorrhea cases among males progressed the most in the Northeast (21.5%) and the Midwest (20.4%) during 2018–2019 and in the West (117.8%) and Northeast (85.7%) during 2013–2017. Hence increasing cases of gonorrhea is boosting the United states Gonorrhea market.

Emergence of Antibiotic-Resistant Gonococcal Strain:

Gonorrhea has progressively increased resistance to the antibiotic medications prescribed to manage it. Following the spread of gonococcal fluoroquinolone resistance, the cephalosporin antibiotics have been the foundation of prescribed treatment for gonorrhea. The emergence of cephalosporin-resistant gonorrhea would significantly complicate the capacity of providers to manage gonorrhea strongly since few antibiotic options are left that are well-studied, simple, well-tolerated, and extremely effective. It is important to continuously observe antibiotic resistance in Neisseria gonorrhoeae and support research and development of distinct treatment regimens.

Restraints

High cost of products

Since most antibiotics, except the most recent ones, are off-patent, the higher cost of moderately newer drugs likely exhibits the enormous regulatory costs of launching a drug to market. The manufacturing cost is high, due to the use of profoundly technologically advanced equipment. Also, the average price of phase 1, 2, and 3 clinical trials across therapeutic areas is approximately USD 4, 13, and 20 million, respectively. Pivotal/phase 3 studies for novel drugs authorized by the Food and Drug Administration (FDA) of the United States cost a median of USD 41,117 per patient.

Stringent regulatory scenarios and social stigma associated with patients visiting STD clinics

People are judged or condemned for being infected with sexually transmitted diseases. Various other types of disorders may also carry some level of social stigma. Nevertheless, the STD stigma is often powerful, which is likely to hamper the market growth. A significant number of people who contract STDs persist undiagnosed, but those who have faced a heavy burden afterward. Even though STDs are demonstrated to be more prevalent than many believe, especially in young people, the stigma encircling STDs still predominates. A lot of that stigma is associated with preconceived notions about sex.

Impact of COVID-19 in the industry

With Covid-19 infections rising globally, multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses on to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off-label indication for these drug classes has to be worked upon. The pandemic has had a noticeable impact on global economic growth. According to the estimates by the United Nations, the global economy could shrink by almost 0.9-1% this year. 

United States Gonorrhea Therapeutics Market: By Infection

Based on infection, the market is categorized as uncomplicated gonococcal infection, complicated gonococcal infection, gonococcal arthritis & gonococcal meningitis, and endocarditis. Amidst this category, Uncomplicated gonococcal infection has a major share in the gonorrhea therapeutics market. Uncomplicated gonorrhea infections are much more prevalent, comprising any anogenital, urogenital, or pharyngeal infection caused by Neisseria gonorrhea that does not result in bacteremia. The rising prevalence among U.S. young population owing to their sedentary lifestyle is one of the major driving factors for the growth of the market. 

Source: BlueWeave Consulting

United States Gonorrhea Therapeutics Market: By Application

Based on application, the United States gonorrhea therapeutics market is segregated into clinics, hospitals & others. The hospital pharmacies market segment is estimated to dominate the gonorrhea therapeutics market by the end of 2031. The sales of gonorrhea therapeutics are projected to witness significant uptake from hospital pharmacies, as hospitals remain selected care centers for patients diagnosed with gonorrhea. The hospital pharmacies will account for a significant major share in 2019.

United States Gonorrhea Therapeutics Market: By Treatment 

Based on treatment, the United States gonorrhea therapeutics market is segregated into monotherapy & dual therapy. The dual therapy segment is dominated by the market, and this trend is expected to continue over the forecast period. Dual therapy with azithromycin and ceftriaxone is prescribed as the first-line regimen for the medication of gonorrhea. Alternatively, a 1 g dose of azithromycin is recommended as a component of dual therapy for gonorrhea, in conjunction with a cephalosporin (i.e., 250 mg of ceftriaxone or 400 mg of cefixime, if ceftriaxone is not an option). WHO recommends dual therapy over monotherapy for people with asymptomatic and symptomatic gonorrhea. 

United States Gonorrhea Therapeutics Market: By Distribution Channel 

Based on the distribution channel, the United States gonorrhea therapeutics market is segregated into hospital pharmacies, retail pharmacies, online pharmacies & others. The hospital's pharmacy segment is estimated to dominate the gonorrhea therapeutics market by the end of 2031. The sales of gonorrhea therapeutics are projected to witness significant uptake from hospital pharmacies, as hospitals remain selected care centers for patients diagnosed with gonorrhea. The hospital pharmacies will account for a value for the major share in the market.

United States Gonorrhea Therapeutics Market: Country insights

The United States is currently capturing the largest market share of the market owing to the well-developed healthcare infrastructure, and favorable government policies regarding the diagnosis and treatment of sexually transmitted diseases. A high awareness level about the disease and favorable reimbursement policies are the factors expected to boost the market during the forecast period. Market growth in the United States is expected to be faster owing to the growing prevalence of the disease in the country and the number of unmet needs in effective diagnosis and treatments of the market.

Recent Development

• In 2019, GSK started a phase III clinical program investigating gepotidacin, the first in a new chemical class of antibiotics called triazaacenaphthylene bacterial topoisomerase inhibitors, in patients with uncomplicated urinary tract infection (UTI, also known as acute cystitis) and urogenital gonorrhea (GC).
• In April 2020, Alembic launched azithromycin tablets. The product is the generic Zithromax tablets. Azithromycin tablets are a macrolide antibacterial drug for mild to moderate infections caused by designated, susceptible bacteria.
• In 2019, Entasis Therapeutics at the World Anti-Microbial Resistance Congress that it has enrolled the first patient in a global phase 3 trial of oral zoliflodacin for the treatment of uncomplicated gonorrhea.

Competitive landscape

Key players for the United States gonorrhea therapeutics market include GlaxoSmithKline plc., Merck & Co., Inc., Pfizer Inc, AstraZeneca, Hologic, Inc., Danaher, Abbott, Becton Dickinson and Company, F. Hoffmann-La Roche Ltd., Alopexx Pharmaceuticals, Melinta Therapeutics & other prominent players. Product approvals, product launches, expansions, and acquisitions are the most commonly adopted strategies by companies to expand their footprints worldwide and meet the growing demand by broadening their product portfolios.

Scope of the Report

Scope of the Report

By Infection

Ø  Uncomplicated Gonococcal Infection

Ø  Complicated Gonococcal Infection

Ø  Gonococcal Arthritis

Ø  Gonococcal Meningitis and Endocarditis

By Treatment

Ø  Monotherapy

Ø  Dual Therapy

By Distribution Channel

Ø  Hospital Pharmacies

Ø  Retail Pharmacies

Ø  Online Pharmacies

Ø  Others

By Route of Administration

Ø  Oral

Ø  Injectable

By Application

Ø  Clinics

Ø  Hospitals

Ø  Others

1.      Research Framework

Additional Customization on Complicated Gonococcal Infection

5.2.1.2.      Complicated Gonococcal Infection –

5.2.1.3.      GonococcalArthritis

5.2.1.4.      Gonococcal Meningitis andEndocarditis

5.2.2.                  By Treatment

5.2.2.1.      Monotherapy

5.2.2.2.      DualTherapy

5.2.3.                  By Distribution Channel

5.2.3.1.      Hospital Pharmacies

5.2.3.2.      Retail Pharmacies

5.2.3.3.      Online Pharmacies

5.2.3.4.      Others

5.2.4.                  By Route of Administration

5.2.4.1.      Oral

5.2.4.2.      Injectable

5.2.5.                  By Application

5.2.5.1.      Clinics

5.2.5.2.      Hospitals

5.2.5.3.      Others

6.      Competitive Landscape

6.1.      List of Key Players and Their Offerings

6.2.      Market/Ranking Share Analysis

6.3.      Competitive Benchmarking, By Operating Parameters

7.      Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook)*

7.1.     GlaxoSmithKlineplc.

7.2.     Merck & Co.,Inc.

7.3.     PfizerInc

7.4.     AstraZeneca

7.5.     Hologic,Inc.

7.6.     Danaher

7.7.     Abbott

7.8.     Becton Dickinson andCompany

7.9.     F. Hoffmann-La RocheLtd.

7.10.    AlopexxPharmaceuticals

7.11.    MelintaTherapeutics

List of Figures